Biotech and Pharmaceuticals Biotechnology

More

  • LONDON, July 26- The heirs of Dolly the sheep are enjoying a healthy old age, proving cloned animals can live normal lives and offering reassurance to scientists hoping to use cloned cells in medicine. Dolly, cloning's poster child, was born in Scotland in 1996. "Overall, the results are suggesting that these animals are remarkably healthy," said Kevin Sinclair of the...

  • Regeneron Pharmaceuticals

    Big drug discoveries have been scant, but investors can find long-term value in some biotech names, said Mark Schoenebaum of Evercore ISI.

  • Opening Bell, July 14, 2016

    Today's bell ringers are Jung-ho Shin, Chief Global Officer of Line Corporation, at the NYSE; and Jeffrey Bacha, Chairman & CEO of Delmar Pharmaceuticals, at the Nasdaq.

  • New highs, is tech next?

    The "Fast Money traders debate the case for the Nasdaq to make a record high alongside the Dow and S&P 500.

  • Juno Therapeutics

    The FDA has put a clinical hold on a phase 2 clinical trial of one of its products after two patients died last week.

  • Why Biotech is still struggling

    CNBC's Meg Tirrell discusses biotech in the bear market and what to expect going forward.

  • Biotech catalysts

    CNBC's Meg Tirrell reports on the health of the biotech sector and what could spur a turnaround in the second half of the year.

  • A lab worker at Spark Therapeutics in Philadelphia, PA.

    The iShares NASDAQ Biotechnology ETF was up more than 3 percent on the week, but down nearly 24 percent this year.

  • Is biotech cheap?

    CNBC's Meg Tirrell reports on the bounce in the biotech sector and how some names could be a good buy at the moment.

  • Biotech rally underway

    CNBC's Meg Tirrell tracks the IBB, which is getting a boost from a new report on the health of Medicare.

  • SYDNEY, June 14- Mesoblast Ltd shares lost more than a third of their value on Tuesday, after drugs giant Teva Pharmaceutical Industries ended a research partnership with the experimental stem cell therapy company. The Australia- based Mesoblast said on Tuesday it had regained full rights to its experimental therapy for advanced chronic heart failure, which...

  • June 13- Mesoblast Ltd on Monday said it had regained full rights to its experimental stem cell therapy for advanced chronic heart failure, which is currently in late stage testing, from Teva Pharmaceutical Industries. While Teva returned its rights to the potential blockbuster treatment without any financial payment, the Israel- based generic drugmaker can...

  • Jennifer Lawrence to star in Theranos movie

    The Hollywood actress will play the role of Theranos CEO Elizabeth Holmes on the big screen.

  • Tom Perkins dies at 84

    Perkins helped grow Silicon Valley's venture capital industry, playing a major role in the early years of the computer and biotech sectors.

  • Hillary Clinton

    The "Fast Money" traders weighed election risks for biotech after Obama officially endorsed Hillary Clinton.

  • *Idea to be discussed June 16, according to internal report. LONDON, June 9- The pharmaceutical industry is considering a radical shift in the way it prices drugs in Europe so companies are rewarded for the clinical benefit of treatments rather than the number of pills sold, according to an internal report. Its proposed "roadmap for change towards outcomes-based...

  • *Idea to be discussed June 16, according to internal report. LONDON, June 9- The pharmaceutical industry is considering a radical shift in the way it prices drugs in Europe so companies are rewarded for the clinical benefit of treatments rather than the number of pills sold, according to an internal report. Its proposed "roadmap for change towards outcomes-based...

  • Amgen research associate in the lab

    Amgen said Wednesday that it has seen positive results for the chronic-migraine prevention drug it has been developing with Novartis.

  • Biotech stocks on the move

    CNBC's Meg Tirrell looks at some pharma and biotech stocks that are making news today.

  • T lymphocytes and cancer cell, computer illustration.

    Shares of Juno Therapeutics jumped on optimistic data from clinical trials of its acute lymphoblastic leukemia therapy.